Should I continue clopidogrel (Plavix) for a history of deep‑vein thrombosis while taking apixaban (Eliquis) for atrial fibrillation?

Stop Plavix (Clopidogrel) – Eliquis Alone is Appropriate

You should discontinue clopidogrel (Plavix) and continue only apixaban (Eliquis) for your atrial fibrillation, as a history of DVT alone does not justify adding antiplatelet therapy to oral anticoagulation. 1

Why Antiplatelet Therapy is Not Indicated for DVT History

DVT Does Not Require Antiplatelet Therapy

• Deep vein thrombosis is a venous thrombotic condition, not an arterial one – it requires anticoagulation, not antiplatelet agents 2
• Clopidogrel (Plavix) is an antiplatelet medication used for arterial thrombotic conditions such as:
  • Acute coronary syndrome (ACS)
  • Recent percutaneous coronary intervention (PCI)
  • Peripheral arterial disease with intervention
  • Recent cerebrovascular events
• Antiplatelet drugs have no role in preventing recurrent venous thromboembolism 2

Eliquis Provides Adequate Anticoagulation for Both Conditions

• Apixaban (Eliquis) is FDA-approved and guideline-recommended for:
  • Stroke prevention in atrial fibrillation 3, 4
  • Treatment and secondary prevention of DVT/PE 3, 5, 6
• The standard dose for AF is 5 mg twice daily (or 2.5 mg twice daily if you meet dose-reduction criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) 3, 1
• One anticoagulant adequately addresses both your AF and DVT history 2

The Dangers of Combining Anticoagulation with Antiplatelet Therapy

Dramatically Increased Bleeding Risk Without Benefit

The 2020 ACC Expert Consensus provides clear guidance that combining antiplatelet therapy with oral anticoagulation significantly increases bleeding risk without providing benefit when there is no arterial indication 1:

• Triple therapy (anticoagulant + aspirin + clopidogrel) increases major bleeding risk by 3.75-fold compared to no therapy 7
• Dual therapy (anticoagulant + clopidogrel) increases bleeding risk by 2.74-fold 7
• Population-based studies show bleeding risks increase in an additive fashion with combination therapy, particularly with warfarin or DOACs 7

When Combination Therapy IS Appropriate

The ACC guidelines specify only three scenarios where adding antiplatelet therapy to anticoagulation is justified 1:

1. Recent PCI (within 12 months):

   • <6 months post-PCI: Stop aspirin, continue clopidogrel + anticoagulant
   • 6-12 months post-PCI: Continue single antiplatelet + anticoagulant

   • 12 months post-PCI: Anticoagulant alone

2. Recent ACS (within 12 months):

   • <12 months: Stop aspirin, continue P2Y12 inhibitor (preferably clopidogrel) + anticoagulant

   • 12 months: Anticoagulant alone

3. Recent CABG (<1 year): Continue aspirin <100 mg daily + anticoagulant

None of these apply to a history of DVT.

Specific Guideline Recommendations

Primary Prevention and Medically Managed Conditions

The ACC Expert Consensus explicitly states 1:

• "For patients on SAPT for SIHD, with no history of an ACS and no prior revascularization who develop AF requiring OAC therapy, the appropriate management is nearly always to stop APT and start an OAC"
• "If such patients were to develop VTE requiring AC therapy, the appropriate management is nearly always to stop APT and start an AC" 1

Antiplatelet Drugs Are Not Alternatives to Anticoagulation

The 2024 ESC Guidelines state unequivocally 8:

• "Antiplatelet drugs, such as aspirin and clopidogrel, are not an alternative to OAC. They should not be used for stroke prevention"
• "Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke" (Class III recommendation)

Common Pitfalls to Avoid

Misconception About "Double Protection"

• Many patients and providers mistakenly believe combining anticoagulation with antiplatelet therapy provides "extra protection"
• This is incorrect and dangerous – it only increases bleeding risk without reducing thrombotic events when there is no arterial indication 8, 7

Inappropriate Continuation from Hospital Discharge

• Sometimes clopidogrel is started during hospitalization for various reasons and inappropriately continued
• Reassess the original indication – if it was only for DVT, it should never have been started 1

Confusing Venous vs. Arterial Thrombosis

• Venous thrombosis (DVT/PE): Requires anticoagulation only
• Arterial thrombosis (MI, stroke, PAD): May require antiplatelet therapy ± anticoagulation depending on timing and other factors
• These are fundamentally different pathophysiologic processes requiring different treatments

What You Should Do

1. Discontinue clopidogrel immediately (no tapering needed)
2. Continue apixaban (Eliquis) at your current prescribed dose
3. Verify your Eliquis dose is appropriate:
   • Standard: 5 mg twice daily
   • Reduced: 2.5 mg twice daily if you meet ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL 3
4. Reassess annually whether continued anticoagulation remains appropriate for your AF (using CHA₂DS₂-VASc score) 1

The evidence is clear: monotherapy with apixaban provides optimal efficacy for both your atrial fibrillation and DVT history, while adding clopidogrel only increases your bleeding risk without any clinical benefit. 1, 8, 2